caa a22 4500 606176527 CHVBK 20210128100748.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s00018-015-1906-2 doi (NATIONALLICENCE)springer-10.1007/s00018-015-1906-2 Extracellular vesicles and atherosclerotic disease [Elektronische Daten] [Dimitry Chistiakov, Alexander Orekhov, Yuri Bobryshev] Circulating extracellular vesicles (EVs) comprise a heterogeneous population of vesicular structures. According to the current paradigm, there are three types of EVs, including exosomes, microvesicles and apoptotic bodies, that are differentiated in their size, formation, and release mechanisms. EVs were shown to act as a ‘post service' that serves a long-distance delivery of complex cellular messages. The cargo of EVs consists of a variety of biomolecules including proteins, DNA, mRNA, and non-coding RNA. In normal or pathological conditions, EVs deliver various molecules to the recipient cells. Those molecules greatly vary depending on the microenvironmental stimuli. In proinflammatory conditions such as atherosclerosis and other cardiovascular diseases, EVs derived from vascular endothelial cells, vascular smooth muscle cells, macrophages, and other circulating immune cells mainly possess proinflammatory properties. However, the capacity of circulating EVs to stably maintain and deliver a variety of biomolecules makes these microparticles to be a promising therapeutic tool for treatment of cardiovascular pathology. To date, circulating EVs were evaluated to be as a source of valuable diagnostic and prognostic biomarkers such as microRNA. Circulating EVs keep a great therapeutic potential to serve as vehicles for targeted therapy of cardiovascular diseases. Springer Basel, 2015 Circulating extracellular vesicles (EVs) nationallicence Microparticles nationallicence Exosomes nationallicence Microvesicles nationallicence Apoptotic bodies nationallicence Atherosclerosis nationallicence Atherogenesis nationallicence Blood vessels nationallicence Circulation nationallicence Chistiakov Dimitry The Mount Sinai Community Clinical Oncology Program, Mount Sinai Comprehensive Cancer Center, Mount Sinai Medical Center, 33140, Miami Beach, FL, USA aut Orekhov Alexander Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Russian Academy of Sciences, 125315, Moscow, Russia aut Bobryshev Yuri Faculty of Medicine, School of Medical Sciences, University of New South Wales, 2052, Sydney, NSW, Australia aut Cellular and Molecular Life Sciences Springer Basel 72/14(2015-07-01), 2697-2708 1420-682X 72:14<2697 2015 72 18 https://doi.org/10.1007/s00018-015-1906-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 review-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00018-015-1906-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Chistiakov Dimitry The Mount Sinai Community Clinical Oncology Program, Mount Sinai Comprehensive Cancer Center, Mount Sinai Medical Center, 33140, Miami Beach, FL, USA aut NATIONALLICENCE 700 1- Orekhov Alexander Laboratory of Angiopathology, Institute of General Pathology and Pathophysiology, Russian Academy of Sciences, 125315, Moscow, Russia aut NATIONALLICENCE 700 1- Bobryshev Yuri Faculty of Medicine, School of Medical Sciences, University of New South Wales, 2052, Sydney, NSW, Australia aut NATIONALLICENCE 773 0- Cellular and Molecular Life Sciences Springer Basel 72/14(2015-07-01), 2697-2708 1420-682X 72:14<2697 2015 72 18